---
title: "Bristol-Myers Squibb (BMY) Receives a Hold from Citi"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292880987.md"
description: "Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $66 price target, while shares closed at $58.72. This follows a July 13 Hold from BMO Capital and contrasts with Bank of America's July 10 Buy rating. Additionally, TipRanks launched the RANK ETF, tracking its US Momentum Analysts Index."
datetime: "2026-07-16T09:06:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292880987.md)
  - [en](https://longbridge.com/en/news/292880987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292880987.md)
generator: "portal-rs"
---

# Bristol-Myers Squibb (BMY) Receives a Hold from Citi

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $66.00. The company’s shares closed yesterday at $58.72.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Meacham is a 5-star analyst with an average return of 14.3% and a 58.58% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Pfizer.

In addition to Citi, Bristol-Myers Squibb also received a Hold from BMO Capital’s Evan Seigerman in a report issued on July 13. However, on July 10, Bank of America Securities reiterated a Buy rating on Bristol-Myers Squibb (NYSE: BMY).

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)](https://longbridge.com/en/news/298666548.md)
- [Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)](https://longbridge.com/en/news/298475819.md)
- [BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod](https://longbridge.com/en/news/298624374.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi disposes of 6,249 common shares worth $403,700.93](https://longbridge.com/en/news/298642486.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**